Genomic Health Presents Four Oncotype DX Studies for Breast and Colon Cancer at ECC 2013

Genomic Health

today announced results from four studies highlighting the value of its Oncotype DX® tests for optimizing treatment for patients with breast and colon cancer.  Three new decision impact studies - including the company's first international decision impact study in colon cancer and additional evidence for the Oncotype DX breast cancer test's significant impact on breast cancer treatment decisions in the United Kingdom (UK) - were among data presented at the European Cancer Congress 2013, taking place September 27-October 1 in Amsterdam.  The results were presented on the heels of the recent National Institute for Health and Care Excellence (NICE) guidance announcement that recommended the use of Oncotype DX "as an option to help clinicians decide whether to prescribe chemotherapy in people with early breast cancer."      (Logo:  http://photos.prnewswire.com/prnh/20130425/SF01493LOGO) "By continuing to invest in research and clinical utility studies, we are able to